[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-tract-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-tract-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100480316","antibiotic-strategy-and-asymptomatic-bacteriuria-in-the-context-of-intra-vesical-botulinum-toxin-a-injections-100480316",false,"NCT05534399","Antibiotic Strategy and Asymptomatic Bacteriuria in the Context of Intra-vesical Botulinum Toxin A Injections.","Assessment of the Interest of a Peri-operative Antibiotic Strategy Applied to Patients With Asymptomatic Bacteriuria Undergoing Intra-vesical Botulinum Toxin A Injections","ANTIBIOBONTA","Inclusion Criteria:\n\n* MS or SCI (traumatic or non-traumatic)\n* Refractory OAB and\u002For DO (failure, intolerance or contra-indication to anti-muscarinic therapy)\n* Treated with intra-vesical botulinum toxin A injections having proved efficacy\n* CISC as the exclusive bladder management\n* AB on pre-operative urine analysis (performed 10 days (+\u002F- 2 days) before intra-vesical BoNTA injections)\n* Exclusion of morphologic urinary tract abnormalities considered as a risk factor for recurrent symptomatic UTI.\n\nExclusion Criteria:\n\n* Having already participated to the study\n* Augmentation cystoplasty\n* Bladder compliance disorders (\\\u003C20 mL\u002FcmH2O)\n* Ongoing cyclic antibiotic therapy\n* Ongoing corticosteroid therapy\n* Modification of immunosuppressive or immunomodulatory therapy in the 3 months before inclusion (MS patients)\n* Antibiotic therapy in the month before inclusion\n* Surgical procedure in the 3 months before and the 6 weeks following inclusion\n* Symptomatic UTI at the time of inclusion\n* Associated neurologic disease\n* Pregnancy or breast feeding\n* Individuals especially in need of protection\n* No informed consent\n* Patients incapable to follow the trial, e.g. because of language problems, psychiatric disorders, dementia and so on\n* Immunocompromised patients","ALL","18 Years",{"count":20,"type":21},526,"ESTIMATED","INTERVENTIONAL",[24],"NA","The study aims to demonstrate that the \"thrifty antibiotic strategy\" applied to MS or SCI patients with asymptomatic bacteriuria prior to BoNTA intravesical injections does not increase the rate of symptomatic post-injection UTIs compared to the current peri-operative antibiotic strategy.\n\nPatients included in the study will be randomized in two balanced-parallel groups, 4 days (+\u002F- 2 days) before intra-vesical BoNTA injections.\n\nGroup 1: Experimental group: \"Sparing antibiotic strategy\" No antibiotic therapy will be administered during the peri-operative period.\n\nGroup 2: Control group: Recommendations - Peri-operative antibiotic strategy An antibiotic therapy will be administered during the peri-operative period. The antibiotic will be selected according to the type of bacteria isolated and the antibiotic susceptibility testing, and started two days before and pursued until two days following intra-vesical BoNTA injections.\n\nThe main objective is to demonstrate the non-inferiority of \"antibiotic saving strategy\" compared to peri-operative antibiotic strategy (current recommendations) for occurrence of symptomatic UTI after intra-vesical BoNTA injections in the management of asymptomatic bacteriuria (AB) among multiple sclerosis (MS) and spinal cord injured (SCI) patients undergoing clean intermittent self-catheterization (CISC).",[27],"Urinary Tract Disease",[29,30,31,32,33,34],"Neurogenic lower urinary tract dysfunction","Clean Intermittent Self Catheterization","Asymptomatic bacteriuria","Botulinum toxin A","Sparing antibiotic strategy","Safety","NOT_YET_RECRUITING","2025-12-18",{"date":38,"type":39},"2025-12-26","ACTUAL",{"date":41,"type":21},"2026-05",{"date":43,"type":21},"2027-05",{"name":45,"class":46},"University Hospital, Lille","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":68,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":47},"100384647","5-alpha-reductase-2-as-a-marker-of-resistance-to-5ari-therapy-100384647","NCT04288427","5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy","Inclusion Criteria:\n\n* Male (physiological);\n* Age ≥ 50;\n* Eligible for treatment with 5ARI therapy;\n* Presence of lower urinary tract symptoms secondary to BPH;\n* Prostate size \\>40cc by digital rectal examination;\n* Absence of prostate nodule, tenderness or firmness;\n* Mildly elevated PSA's \\>1.5 ng\u002Fml and ≤ 40 ng\u002Fml;\n* Undergoing clinically indicated prostate biopsy for elevated prostate-specific antigen (PSA).\n\nExclusion Criteria:\n\n* Diagnosis of any prostatic malignancy or precancerous lesions (atypical glandular foci and prostatic intraepithelial neoplasia);\n* Treatment with 5ARI (Finasteride or Dutasteride) within six months of study enrollment;\n* Current urinary tract infection;\n* Previous pelvic radiation;\n* Previous treatment with demethylating drugs;\n* Diagnosis of multiple sclerosis, Alzheimer's, Parkinson's, neurological deficits in the judgment of the investigator;\n* Unable or unwilling to undergo MRI due to implants, claustrophobia, etc.","MALE","50 Years",{"count":57,"type":21},120,[24],"The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified prior to offering this treatment and they can be offered alternative treatment strategies in its place. The aim is to see if noninvasive techniques such as MRI can detect inflammation of the prostate to assist with early detection of those who will and who will not respond to Finasteride.",[61,62,63,64,65,66,67,27],"Benign Prostatic Hyperplasia","Prostate Hyperplasia","Prostate Disease","Prostate Hypertrophy","Prostate Pain","Lower Urinary Tract Symptoms","Urinary Obstruction",[69,70],"Finasteride","5 Alpha Reductase","RECRUITING","2025-10-27",{"date":74,"type":39},"2025-10-28",{"date":76,"type":39},"2020-09-25",{"date":78,"type":21},"2026-11-30",{"name":80,"class":46},"Beth Israel Deaconess Medical Center",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":47},"100451068","infectious-complications-after-cystectomy-a-prospective-observational-study-100451068","NCT05153694","Infectious Complications After Cystectomy: A Prospective Observational Study","Inclusion Criteria:\n\n* Disease which requires removal of the urinary bladder\n\nExclusion Criteria:\n\n* Patient does not want to participate",{"count":88,"type":21},200,"OBSERVATIONAL","Patients undergoing cystectomy for either oncological or non-oncological indications are prospectively enrolled following informed consent. This study design incorporates a comprehensive medical history, detailed prospective documentation of clinicopathological parameters, and serial measurements of infectious markers pre- and post-operatively. In-hospital complications are meticulously recorded, and long-term outcomes assessed through structured follow-up interviews at 3, 6, and 12 months. These follow-ups utilize standardized questionnaires to evaluate post-discharge infectious complications and gather patients' perspectives on their in-hospital experiences, providing a robust understanding of both clinical outcomes and patient-reported experiences.",[92,93,94,95,96,97,98,27],"Bladder Cancer","Infections","Infection, Bacterial","Infection, Hospital","Infection Wound","Urinary Tract Infections","Urinary Bladder Diseases","2024-09-13",{"date":101,"type":39},"2024-09-19",{"date":103,"type":39},"2021-12-01",{"date":105,"type":21},"2025-12-31",{"name":107,"class":46},"Ludwig-Maximilians - University of Munich"]